carboplatin + paclitaxel + prednisolone

The combination of carboplatin + paclitaxel + prednisolone is a chemotherapy regimen used in cancer treatment. This combination brings together two established chemotherapeutic agents (carboplatin and paclitaxel) with a corticosteroid (prednisolone). ## Mechanism and Administration Carboplatin and paclitaxel work through different mechanisms to destroy rapidly dividing cancer cells. Carboplatin is an organoplatinum antineoplastic alkylating agent that interferes with DNA replication[6]. Paclitaxel is a taxane that disrupts microtubule function, which is essential for cell division. The administration typically involves: - Paclitaxel given as an intravenous infusion over 3 hours - Carboplatin administered as an intravenous infusion over 30-60 minutes - Prednisolone given orally as tablets ## Clinical Applications While the specific combination of all three agents isn't explicitly detailed in the search results, carboplatin + paclitaxel is used to treat various cancers including: - Ovarian cancer - Lung cancer - Head and neck cancer - Cervical cancer - Endometrial cancer[5][6] The addition of prednisolone (a corticosteroid) likely serves to: - Reduce allergic reactions to paclitaxel - Manage nausea and vomiting - Decrease inflammation - Potentially enhance the efficacy of the chemotherapy agents ## Side Effects Common side effects of this combination may include: - Hematologic toxicities: neutropenia, anemia, and thrombocytopenia[1][2] - Kidney effects requiring monitoring of renal function[3] - Potential for allergic reactions, particularly to paclitaxel - Nausea and vomiting - Abdominal pain and cramps[5] - Changes in mineral levels in the blood (sodium, calcium, magnesium, potassium)[5] ## Dosing Considerations The dosing regimen varies based on cancer type and patient factors: - Paclitaxel is typically given at doses around 135 mg/m² - Carboplatin dosing often follows the Calvert formula to achieve a specific AUC (area under the curve)[1][7] - Prednisolone dosing would be determined based on patient needs and protocol requirements Treatment is usually administered in cycles, with each cycle lasting 3-4 weeks, and patients may receive up to 8 cycles depending on their response and tolerance[5].